

# Workshop

## „Tumor immunology“ of the DGfI

21st of May 2015  
Location: Lecture Hall 4 at the University  
Hospital Kroellwitz, Halle

**Chair: Marc Schmitz, Selvan Senthamil**

**12.45 – 13.00 Barbara Seliger: Introduction**

**13.00 –13.15 Zhao Fang (Essen, D)**

Genetic heterogeneity of intra-patient metastases restricts T-cell recognition of malignant melanoma

**13.15 – 13.30 Simon Jasinski-Bergner (Halle, D)**

HLA-E expression in renal cell carcinoma and its association with immune cell infiltration

**13.30 –13.45 Elisabeth Geyer (Dresden, D)**

Phenotype of infiltrating human 6-sulfo LacNAc dendritic cells in renal and colon cancer

**13.45 – 14.00 Dagmar Quandt (Halle, D)**

Chemotherapy induced modulation of immune recognition in murine and human tumors

**14.00 – 14.15 Kathrin Renner (Regensburg, D)**

Glycolytic or mitochondrial restriction preserves human CD4 and CD8 T cell effector function

**14.15 – 14.30 Frank Momburg (Heidelberg, D)**

Altered T and NK cell activation in an simulated tumor microenvironment

**14.30 – 14.45 Elisa Cappuzzello (Padova, I)**

Combined therapy of CIK cells and monoclonal antibodies for ovarian cancer: a preclinical study

**14.45 – 15.00 Stefanie Koristka (Dresden, D)**

Flexible antigen-specific redirection of human regulatory T cells via a novel universal chimeric antigen receptor system

**15.00 - 15.15 Elena Faitschuk (Cologne, D)**

A novel CAR in a physiologic antibody format to redirect modified T cells

**Coffe Break**

## Chair: Dagmar Riemann, Michael Bachmann

### **15.45 –16.15 Samir Khleif (Augusta, USA)**

Strategies and design for combination immunotherapie

### **16.15 –16.30 Marc Cartellieri (Dresden, D)**

Switching T cells on and off: A novel modular retargeting platform technology for precise control of CAR T cell reactivity

### **16.30 – 16.45 Lucia Poncette (Berlin, D)**

Human HLA-DR4-restricted T cell receptors against NY-ESO-1 from a non-tolerant host

### **16.45 –17.00 Eva Amann (Mainz, D)**

HLA-A2-restricted MDM2 (81-88) epitope as a new target antigen for TCR therapy

### **17.00 – 17.15 Sara Valpione (Padova, I)**

Personalized medicine: development and external validation of a prognostic model for metastatic melanoma patients treated with ipilimumab

### **17.15 – 17.30 Ann-Charlott Schneider (Cologne, D)**

NK-cell based immunoligands as novel treatment option against haematological tumors

### **17.30 – 17.45 Alexandra Martyniszyn (Cologne, D)**

Dual targeting by a bispecific Chimeric Antigen Receptor (CAR) for the recognition of antigen-loss subset of leukemic cells

### **17.45 – 18.00 Claudia Arndt (Dresden, D)**

Improved killing of AML blasts by dual-targeting of CD123 and CD33 via a Ab-based modular T cell retargeting system

### **18.00 – 18.20 Thomas-Oliver Kleen (Berlin, D)**

Next generation immune monitoring using epigenetic markers

## **Summary Hinrich Abken**

**We thank our sponsors:** Beckman Coulter GmbH, Becton Dickinson GmbH, Biodesix, Bristol-Myers Squibb (3.000 €), City of Halle, DFG, DGfI, Epiontis GmbH, iba Solutions for Life Sciences, JPT Peptide Technologies GmbH, Lipocalyx GmbH, Miltenyi Biotec GmbH, Ministerium für Wissenschaft und Wirtschaft Sachsen-Anhalt, NHDyeAGNOSTICS, Pfizer Pharma GmbH (1.000 €), Saalesparkasse Halle, Sarstedt, SERVA GmbH, SITC